End Stage Renal Disease, Secondary Hyperparathyroidism
Conditions
Brief summary
This study was performed to determine whether calcitriol provides a therapeutic advantage to alfacalcidol for treatment of secondary hyperparathyroidism in ESRD patients.
Detailed description
Secondary hyperparathyroidism has a significant impact on morbidity and mortality in advanced chronic kidney disease (CKD).Both nonselective and selective vitamin D receptor activators (VDRAs) are demonstrated in many studies for their efficacy on suppression of PTH. Most of them are quite expensive and unavailable in many countries. Calcitriol and alfacalcidol are less expensive and worldwidely distributed. There is only one short-term study which directly compares these two drugs. This study demonstrates that calcitriol is superior to alfacalcidol. However, alfacalcidol is a prohormone of calcitriol. It has to be converted by 25-hydroxylase at the liver to generate 1,25-dihydroxyvitamin D3 to act on target cells. Many pharmacokinetics studies demonstrate that alfacalcidol has lower AUC compared to calcitriol if they are administered in the same dose. Therefore, the authors hypothesize that alfacalcidol may be equivalently efficacious as calcitriol if its dose is adjusted according to the pharmacokinetics studies.
Interventions
DRUGalfacalcidol and calcitriol
The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
Sponsors
Mahidol University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic hemodialysis patients who underwent scheduled hemodialysis for at least 3 months with secondary hyperparathyroidism (intact PTH levels \> 300 pg/mL)
Exclusion criteria
* (1) age \< 18 years (2) hypersensitivity to calcitriol or alfacalcidol (3) inadequate dialysis \[defined as single-pooled Kt/V (sp-Kt/V) \<1.2 and \<2.0 for thrice a week and twice a week hemodialysis\] (4) corrected serum calcium \>10.2 mg/dL or serum phosphate \>6 mg/dL after adjusting dialysate calcium and phosphate binders (5) diameter of parathyroid gland \>10 mm (6) pregnancy or lactation (7) liver cirrhosis (8) active kidney transplantation (9) previous parathyroidectomy (10) malignancy or chronic infection/inflammation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of intact parathyroid hormone levels | 48 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hypercalcemia and hyperphosphatemia | 48 weeks | proportion of the patients who achieved a target PTH, changes in plasma calcium and phosphorus, the proportion of the patients who had hypercalcemia (plasma corrected calcium \> 10.8 mg/dl), hyperphosphatemia (plasma phosphorus \> 6.0 mg/dl) and calcium-phosphorus products \> 55 mg2/dl2 between groups. |
Countries
Thailand
Outcome results
None listed